One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement

Annals of the Rheumatic Diseases

Volumn 67, Issue 2, 2008, Pages 168-174

  Deberg, M ^a   Dubuc, J E ^b   Labasse, A ^a   Sanchez, C ^a   Quettier, E ^b   Bosseloir, A ^c   Crielaard, J M ^a   Henrotin, Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Hospital Princess Paola   (Belgium)

^c Zentech SA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COLL2 1 NITRIC OXIDE; COLL2 1 PROTEIN; MYELOPEROXIDASE; NITRIC OXIDE; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE BIOPSY; CARTILAGE CELL; CHONDROPATHY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HIP OSTEOARTHRITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KNEE ARTHROPLASTY; KNEE OSTEOARTHRITIS; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERUM; TOTAL HIP PROSTHESIS;

AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PEPTIDE FRAGMENTS; PEROXIDASE; REFERENCE VALUES;

EID: 38749124790     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.073452     Document Type: Article

References (46)

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006;14:723-7.
3. Garnero P. Biochemical markers in osteoarthritis: will they measure up? Nat Clin Pract 2006;2:116-7.
4. Garnero P. Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep 2006;8:37-44.
5. Kraus VB. Do biochemical markers have a role in osteoarthritis diagnosis and treatment? Best Practice Res 2006;20:69-80.
6. Birmingham D, Vilim V, Kraus VB. Collagen biomarkers for arthritis applications. Biomark Ins 2006;2:61-7.
7. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534- 45.
8. Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Meth 2004;294:145-53.
9. Hellio Le Graverand MP, Brandt KD, Mazzuca SA, Katz BP, Buck R, Lane KA, et al. Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthritis Cartilage 2006;14:1189-95.
10. Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, et al. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 1994;93:1722-32.
11. Deberg M, Labasse A, Christgau S, Cloos P, Bang Henriksen D, Chapelle JP, et al. New serum biochemical markers (Coll2-1 and Coll2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005;13:258-65.
12. Charni N, Juillet F, Garnero P. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2005;52:1081-90.
13. Croucher LJ, Hollander AP. Differential detection of type II collagen N-terminal and C-terminal denaturation epitopes in degrading cartilage. Mol Pathol 1999;52:323-31.
14. Elsaid KA, Chichester CO. Review: collagen markers in early arthritic diseases. Clin Chim Acta 2006;365:68-77.
15. Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-15.
16. Henrotin Y, Deberg M, Dubuc JE, Quettier E, Christgau S, Reginster JY. Type II collagen peptides for measuring cartilage degradation. Biorheology 2004;41:543-7.
17. Deberg MA, Labasse AH, Collette J, Seidel L, Reginster JY, Henrotin YE. One-year increase of Coll2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 2005;13:1059-65.
18. Deby-Dupont G, Deby C, Lamy M. Neutrophil myeloperoxidase revisited: its role in health and disease. Intensivmed 1999;36:500-13.
19. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther 2006;111:16-26.
20. Brennan ML, Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 2003;14:353-9.
21. Sampson JB, Ye Y, Rosen H, Beckman JS. Myeloperoxidase and horseradish peroxidase catalyze tyrosine nitration in proteins from nitrite and hydrogen peroxide. Arch Biochem Biophys 1998;356:207-13.
22. Rees MD, Hawkins CL, Davies MJ. Hypochlorite and superoxide radicals can act synergistically to induce fragmentation of hyaluronan and chondroitin sulphates. Biochemical J 2004;381:175-84.
23. Shabani F, McNeil J, Tippett L. The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by antirheumatic drugs. Free Radical Res 1998;28:115- 23.
24. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
25. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998;44:2281-9.
26. Sweet MB, Coelho A, Schnitzler CM, Schnitzer TJ, Lenz ME, Jakim I, et al. Serum keratan sulfate levels in osteoarthritis patients. Arthritis Rheum 1988;31:648-52.
27. Garnero P, Sornay-Rendu E, Arlot M, Christiansen C, Delmas PD. Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. Arthritis Rheum 2004;50:3137-44.
28. Meulenbelt I, Kloppenburg M, Kroon HM, Houwing-Duistermaat JJ, Garnero P, Hellio Le Graverand MP, et al. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis 2006;65:360-5.
29. Henrotin Y, Deby-Dupont G, Deby C, De Bruyn M, Lamy M, Franchimont P. Production of active oxygen species by isolated human chondrocytes. Brit J Rheumatol 1993;32:562-7.
30. Tiku ML, Liesch JB, Robertson FM. Production of hydrogen peroxide by rabbit articular chondrocytes. Enhancement by cytokines. J Immunol 1990;145:690-6.
31. Kakinuma T, Yasuda T, Nakagawa T, Hiramitsu T, Akiyoshi M, Akagi M, et al. Lectin-like oxidized low-density lipoprotein receptor 1 mediates matrix metalloproteinase 3 synthesis enhanced by oxidized low-density lipoprotein in rheumatoid arthritis cartilage. Arthritis Rheum 2004;50:3495-503.
32. Shah R, Raska K Jr, Tiku ML. The presence of molecular markers of in vivo lipid peroxidation in osteoarthritic cartilage: a pathogenic role in osteoarthritis. Arthritis Rheum 2005;52:2799-807.
33. Tiku ML, Allison GT, Naik K, Karry SK. Malondialdehyde oxidation of cartilage collagen by chondrocytes. Osteoarthritis Cartilage 2003;11:159-66.
34. Karan A, Karan MA, Vural P, Erten N, Tascioglu C, Aksoy C, et al. Synovial fluid nitric oxide levels in patients with knee osteoarthritis. Clin Rheumatol 2003;22:397-9.
35. Spreng D, Sigrist N, Schweighauser A, Busato A, Schawalder P. Endogenous nitric oxide production in canine osteoarthritis: detection in urine, serum, and synovial fluid specimens. Vet Surg 2001;30:191-9.
36. van der Harst M, Bull S, Brama PA, Barneveld AB, van Weeren PR, van de Lest C. Nitrite and nitrotyrosine concentrations in articular cartilage, subchondral bone, and trabecular bone of normal juvenile, normal adult, and osteoarthritic adult equine metacarpophalangeal joints. J Rheumatol 2006;33:1662-7.
37. Loeser RF, Carlson CS, Del Carlo M, Cole A. Detection of nitrotyrosine in aging and osteoarthritic cartilage: correlation of oxidative damage with the presence of interleukin-1beta and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum 2002;46:2349-57.
38. Kaur H, Halliwell B. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett 1994;350:9-12.
39. Ersoy Y, Ozerol E, Baysal O, Temel I, MacWalter RS, Meral U, et al. Serum nitrate and nitrite levels in patients with rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis. Ann Rheum Dis 2002;61:76-8.
40. Farrell AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992;51:1219-22.
41. Punzi L, Oliviero F, Plebani M. New biochemical insights into the pathogenesis of osteoarthritis and the role of laboratory investigations in clinical assessment. Crif Rev Clin Lab Sci 2005;42:279-309.
42. Pearle AD, Scanzello CR, George S, Mandl LA, Dicarlo EF, Peterson M, et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage 2006;15:516-23.
43. van der Vliet A, Eiserich JP, O'Neill CA, Halliwell B, Cross CE. Tyrosine modification by reactive nitrogen species: a closer look. Arch Biochem Biophys 1995;319:341-9.
44. Henrotin YE, Zheng SX, Deby GP, Labasse AH, Crielaard JM, Reginster JY. Nitric oxide downregulates interleukin 1beta (IL-1beta) stimulated IL-6, IL-8, and prostaglandin E2 production by human chondrocytes. J Rheumatol 1998;25:1595-601.
45. Palmer RM, Hickery MS, Charles IG, Moncada S, Bayliss MT. Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Comm 1993;193:398-405.
46. Stadler J, Stefanovic-Racic M, Billiar TR, Curran RD, McIntyre LA, Georgescu HI, et al. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J Immunol 1991;147:3915-20.